Skip to main content
Livermore
Livermore
ZHEN

Aquestive Therapeutics, Inc.

AQST
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001398733

In the last 90 days, Aquestive Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 185 institutions reported holding it in 13F filings for Q2 2026, worth $299.5M in total; no superinvestor holds it.

Holders of 5% or more of AQST

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Aquestive Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of AQST
HolderLatest formStakeChangeFirst filedLatest filingFiling
Bratton Douglas K13G/A11.10%10.1M shares–Feb 13, 20251 filingFeb 13, 2025SEC
BlackRock, Inc.13G/A5.30%6.43M shares–Oct 17, 20251 filingOct 17, 2025SEC
RTW Investments, LP13G5.20%6.25M sharesNewNov 14, 20251 filingNov 14, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

4 Schedule 13D and 13G filings on Aquestive Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on AQST
Filed (ET)FilerFormStakeChangeEvent dateFiling
Nov 14, 20258:24 AM ETRTW Investments, LPand 1 other13G5.20%6.25M sharesNewSep 30, 2025SEC
Oct 17, 20256:05 PM ETBlackRock, Inc.13G/A5.30%6.43M shares–Sep 30, 2025SEC
Feb 14, 20256:12 PM ETVenrock Healthcare Capital Partners III, L.P.and 6 others13G/A2.90%2.63M shares–Below 5%Dec 31, 2024SEC
Feb 13, 202511:38 AM ETBratton Douglas Kand 5 others13G/A11.10%10.1M shares–Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Aquestive Therapeutics, Inc. shares.

No Form 144 notices for Aquestive Therapeutics, Inc. are on file.